Doxorubicin (HCl)

Overview

Doxorubicin (HCl)/Adriamycin HCl is antineoplastic agent, also called as anticancerous drug. Doxorubicin (HCl) is the prototype agent of anthracycline antibiotic, isolated from Streptomyces peucetius var caesius. It contains an amino sugar and an anthracycline ring. Doxorubicin (HCl) is among the most useful cytotoxic anticancerous drugs. It has a broad spectrum of potent activity against many different types of cancers specially haematologic malagnancies. Doxorubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic effects and to reduce the side effects or toxcities.

Categories

• 8 Antineoplastics, immunomodulators and drugs used in palliative care
  • 8.2 Cytotoxic (anti-neoplastic) drugs

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Drug Interactions

Side Effects

Dosage

Doxorubicin (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
60 to 75 mg/sq.meter	68 (67.5)	As recommended.	IV	Every 3rd Week, or As Required
Paedriatic Dosage (20kg)
60 to 90 mg/sq.meter	75 (75)	As recommended.	IV Infusion	Over 96 Hours, every 3-4 weeks
Neonatal Dosage (3kg)
No data regarding the neonatal dosage details of Doxorubicin (HCl) is available.

High Risk Groups

Warning / Precautions

Doxorubicin should be used with caution in patients who have had previous myelosuppressive therapy such as chemotherapy or radiation therapy, in patients with tumor infiltrate of the bone,with hepatic disease, in patients with dental disease. Dental work should be performed prior to initiating doxorubicin therapy, or deferred until blood counts return to normal. It should be usedwith extreme caution in patients with cardiac disease. Patients with active infection should betreated prior to receiving doxorubicin, the dose should be reduced or discontinued in patients whodevelop such infections. Patients should be observed closely for signs of cardiotoxicity; early recognition is essential for successful treatment of doxorubicin-induced cardiac toxicity. A reduction in dosage and/or dosage interval is indicated in patients with moderate to severe stomatitis. Doxorubicin therapy should not be initiated until patients recover normal hematopoiesis after bone marrow depression. Patients with pre-existing heart failure, with angina, or with cardiac arrhythmias are not good candidates to receive doxorubicin. It should not be administered during pregnancy and lactation.

Storage Conditions

Interference in Pathology

Brands / Trade Names of Doxorubicin (HCl)

Manufacturers of Doxorubicin (HCl) in Pakistan

Back to top